BioSpace News Archive

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the presentation of data from two clinical trials for PEGPH20 (pegvorhyaluronidase alfa) in patients with advanced pancreas and metastatic breast cancer.

Abarca announced at the opening of the Academy of Managed Care Pharmacy Nexus Conference that PerformRx, a leading national full-service PBM headquartered in Philadelphia, PA, has selected Darwin, Abarca’s PBM technology platform, to serve its key clients.

Bradley is the former CEO of RxHub - now Surescripts - a healthcare technology company that has developed a nationwide electronic information exchange

Reistone Biopharma Company Limited today announced the US FDA approval of IND for phase II clinical trial to investigate the efficacy and safety of selective Janus Kinase 1 inhibitor (JAK1) in moderate to severe ulcerative colitis (UC) in the United States.

Showcasing eyecare devices and teleretinal solutions at the American Academy of Ophthalmology 2018 meeting, Canon U.S.A., Inc., a leader in digital imaging solutions, will provide attendees the opportunity to see how the Canon eyecare product portfolio can help improve their practice workflows and help them meet the retinal imaging needs of their patients.

CEI Vision Partners announces that Retina Physicians and Surgeons of Dayton, Ohio is now the newest partner practice of the CVP organization which was formed in May 2018.

AtriCure, Inc. today announced that it will be participating in upcoming investor conferences.

Regulus Therapeutics Inc. today announced that it will present preclinical data regarding RGLS4326, a single stranded, chemically modified oligonucleotide in clinical development for Autosomal Dominant Polycystic Kidney Disease (ADPKD), at the American Society of Nephrology’s (ASN) Kidney Week 2018 meeting being held October 23-28, 2018 in San Diego, CA.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new long-term data from the open-label period of the VOYAGE 1 clinical study.

Loxo Oncology, Inc. (Nasdaq: LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers, and Bayer AG, Germany, today announced updated clinical data for larotrectinib, an investigational oral, selective, and CNS-active TRK inhibitor, in adult and pediatric patients with TRK fusion cancers.